This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a "k-hole".
Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a "k-hole".
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter (SERT), and 42 nM for the sigma-1 receptor <ref name="AMCD">Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012</ref> It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP.<ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref>
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter (SERT), 42 nM for the sigma-1 receptor and 2960 nM for Histamine H1 receptor. <ref name="AMCD">Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012</ref> It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP.<ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref>
Although 3-MeO-PCP was once claimed to possess opioid or dopaminergic activity,<ref name="chemist">Interview with a ketamine chemist: or to be more precise, an arylcyclohexylamine chemist | http://www.vice.com/read/interview-with-ketamine-chemist-704-v18n2</ref> this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.<ref name="AMCD2">The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059334</ref> 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a [[research chemical]] in 2011.<ref name="PCP2MXE" />
Although 3-MeO-PCP was once claimed to possess opioid or dopaminergic activity,<ref name="chemist">Interview with a ketamine chemist: or to be more precise, an arylcyclohexylamine chemist | http://www.vice.com/read/interview-with-ketamine-chemist-704-v18n2</ref> this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.<ref name="AMCD2">The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059334</ref> 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a [[research chemical]] in 2011.<ref name="PCP2MXE" />
It is strongly discouraged to take this substance in high dosages, for multiple days in a row, or in combination with other substances that increase the risk of psychosis. Please see this section for more details.
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
3-MeO-PCP was first synthesized in 1979 in an investigation of phencyclidine (PCP) derivatives. Its activity in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle reported qualitative similarities to PCP along with comparable potency.[5]
Like other arylcyclohexlyamines, 3-MeO-PCP induces a state referred to as "dissociative anesthesia", although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. It is commonly taken orally and nasally, although it may also be smoked and injected. It has been noted for its subtle come up and tendency to produce delusions of sobriety, which can lead to compulsive redosing.
3-MeO-PCP is rarely sold on the streets and almost exclusively obtained as a gray area research chemical through the use of online vendors[6], where it is commonly used as a recreational substance and, more rarely and controversially, as an entheogen.[citation needed] Due to its potent dissociative, stimulant and hallucinogenic effects, commonly reported habit-forming properties, as well as unknown toxicity profile, it is strongly recommended that one use proper harm reduction practices if using this substance.
3-Methoxyphencyclidine, or 3-MeO-PCP, is a synthetic dissociative of the arylcyclohexylamine class. 3-MeO-PCP contains cyclohexane, a six-member saturated ring, bonded to two additional rings at R1. One of these rings is a piperidine ring, a nitrogenous six member ring, bonded at its nitrogen group. The other ring is an aromatic phenyl ring, substituted at R3 with a methoxy group.
3-MeO-PCP is a PCP derivative and structurally analogous to 4-MeO-PCP.
3-MeO-PCP acts as an NMDA receptor antagonist. A specific subtype of glutamate receptor, NMDA (N-Methyl-D-Aspartate), modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open.
Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a "k-hole".
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter (SERT), 42 nM for the sigma-1 receptor and 2960 nM for Histamine H1 receptor. [7] It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP.[8]
Although 3-MeO-PCP was once claimed to possess opioid or dopaminergic activity,[9] this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.[10] 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a research chemical in 2011.[5]
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
Stimulation - This substance is regarded to be noticeably stimulating in comparison to other dissociatives such as ketamine, MXE, or DCK. The stimulation it presents is clean and comfortable in a manner which is far closer to that of 3-MeO-PCE than that of O-PCE.
Spontaneous bodily sensations - The body high of this compound can be described in terms of its style variations as a motionless, constant, sharp, all-encompassing, and euphoric activation of nerve endings across the body.
Physical euphoria - 3-MeO-PCP has been reported to more readily induce euphoria than most other dissociatives, such as ketamine or diphenidine, especially of the manic variant.
Tactile enhancement or Tactile suppression - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and anesthesia.
Pain relief - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only in the stronger to heavier dose ranges.
Bodily control enhancement or Motor control loss - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards motor control
Spatial disorientation - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses.
Seizure - The extent to which this effect can be produced is unknown but can likely happen in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued or undernourished.
Compulsive redosing - This effect is more prominent based on the route of administration used. For example, it is especially present when smoked or vaporized, due to the relative abruptness of the substance entering and leaving the bloodstream.
Mania - This effect is reportedly more common on 3-MeO-PCP than most other dissociatives. It typically occurs during the offset of the experience, but can also occur during the onset and come up as well.
Psychosis - This effect has been reported to be more common on 3-MeO-PCP than most other dissociatives, such as MXE or ketamine. It typically occurs during the offset of the experience, but can also occur during the onset and come up as well.
Delusion - Like psychosis, this effect is reportedly more common on 3-MeO-PCP than most other dissociatives.
Increased libido - This is reported to be present at lower dosage ranges.
Visual effects
Visual acuity enhancement or Visual acuity suppression - While lower doses of this compound tend to produce mild visual acuity enhancements, this effect quickly disappears as one's general visual faculties become suppressed as the dose is increased.
The toxicity and long-term health effects of recreational 3-MeO-PCP use has not been studied in any scientific context and the exact toxic dosage is unknown. This is because 3-MeO-PCP has very short history of human usage.
There is one death involving this substance recorded in the medical literature. In this case, the invidual's cause of death was determined to be from a combination of 3-MeO-PCP, amphetamine, and diphenhydramine.[11]
Tolerance and addiction potential
The chronic use of 3-MeO-PCP can be considered highly addictive with a high potential for adverse side effects such as psychosis. In comparison to other dissociatives, 3-MeO-PCP has been reported to be more addictive than MXE, diphenidine, ephenidine, DCK, and ketamine. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. There have been multiple reports across the internet of people becoming seriously addicted daily users of this substance so serious precautions and considerations should be taken before trying this substance.
Tolerance to many of the effects of 3-MeO-PCP develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 3-MeO-PCP presents cross-tolerance with [[Cross-tolerance::all dissociatives]], meaning that after the consumption of 3-MeO-PCP, all dissociatives will have a reduced effect.
Psychosis
3-MeO-PCP has been reported to cause psychosis, delusions, and mania at a significantly higher rate than other dissociatives such as ketamine, diphenidine, or MXE. There are a large number of experience reports online which describe states of "psychotic delirium, amnesia, mania, and other serious consequences" after abusing the drug.[12][13][14] In some cases, it has resulted in hospitalization and occasionally has taken up to a week or more to resolve.[15][16][17][18][19]
It is strongly recommended that one exercise extreme caution and harm reduction practices when using this substance.
Users should avoid taking the drug multiple days in a row or becoming dependent/addicted to it as this seems to be the main common factor in the observed incidences of severe adverse effects.
The recommended dosage range should not be exceeded as high doses can trigger these effects as well.
Users should start with extremely low doses and work their way up as slowly as possible. Volumetric liquid dosing should preferably be used due to the drug's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.[20]
Compulsive redosing before one has fully sobered up is not recommended and can result in too high of a dose.
Due to the risk of psychosis, it is not recommended to combine this drug with other substances, especially stimulants, psychedelics, or other dissociatives like MXE. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the accurate administration of the intended dose.
Urinary tract effects
In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine, but to a lesser extent. This is possibly because 3-MeO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:
Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
Urinary urgency - This can be described as a sudden, compelling need to urinate.
Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
Hematuria - Hematuria is visible blood in the urine.
Incontinence - This is the leakage of urine.
These effects can be mitigated by refraining from using 3-MeO-PCP regularly (on a daily or weekly basis) and manually limiting one's usage of the substance.
Dangerous interactions
Warning:Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Psychedelics - This combination is not advised because 3-MeO-PCP has been reported to cause extreme psychological disturbances such as psychosis and mania at a significantly higher rate than other dissociatives.[12][13][14]
Stimulants - This combination is not advised because 3-MeO-PCP has been reported to cause extreme psychological disturbances such as psychosis and mania at a significantly higher rate than other dissociatives.[12][13][14]
As such, it may contain incomplete or wrong information. You can help by expanding it.
Austria: 3-MeO-PCP is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
Germany: On November 21, 2015, 3-MeO-PCP was added to "Anlage II" of the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.[21]
Sweden: Sweden's public health agency suggested classifying 3-MeO-PCP as a hazardous substance on November 10, 2014.[22]
United Kingdom: 3-MeO-PCP is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.[23]
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
↑ 5.05.1Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
↑Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
↑Bakota, E., Arndt, C., Romoser, A. A., & Wilson, S. K. (2016). Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method. Journal of Analytical Toxicology, 40(7), 504–510. http://doi.org/10.1093/jat/bkw056
↑Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/26295489
